Table 4.
Comparison of variations (T1–T0) in disease-specific patient-reported outcomes between patients who were visited at least once and those who were assessed by telemedicine only
| Rheumatoid arthritis | Psoriatic arthritis | Ankylosing spondylitis | ||||
|---|---|---|---|---|---|---|
| At least 1 visit | Univariate (95% CI) | Multivariate* (95% CI) | Univariate (95% CI) | Multivariate* (95% CI) | Univariate (95% CI) | Multivariate* (95% CI) |
| N = 189 | – | – | ||||
| RADAI | − 0.33 (− 0.71, 0.06) | − 0.21 (− 0.58, 0.16) | – | – | – | – |
| ROAD | − 0.21 (− 0.51, 0.09) | − 0.16 (− 0.45, 0.13) | – | – | – | – |
| N = 185 | − | – | ||||
| PROCLARA | − 0.32 (− 0.67, 0.02) | − 0.24 (− 0.57, 0.08) | – | – | – | – |
| N = 190 | N = 82 | N = 58 | ||||
| FACIT | 1.14 (− 0.50, 2.78) | 0.96 (− 0.64, 2.57) | 0.46 (− 2.35, 3.27) | 0.34 (− 2.29, 2.97) | 2.46 (− 1.64, 6.56) | 0.65 (− 3.32, 4.61) |
| – | – | N = 55 | ||||
| BASDAI | – | – | – | – | 0.33 (− 0.16, 0.83) | 0.38 (− 0.13, 0.90) |
| BASG | – | – | – | – | − 0.02 (− 1.86, 1.82) | 0.46 (− 1.38, 2.31) |
| – | – | N = 54 | ||||
| BASFI | – | – | – | – | − 0.43 (− 1.98, 1.12) | 0.03 (− 1.66, 1.73) |
CI Confidence interval, RADAI Rheumatoid Arthritis Disease Activity Index, ROAD Recent-Onset Arthritis Disability, PROCLARA Patient Reported Outcomes CLinical ARthritis Activity, FACIT Functional Assessment of Chronic Illness Therapy, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASG Bath Ankylosing Spondylitis Global Index, BASFI Bath Ankylosing Spondylitis Functional Index
*Adjusted for age, gender, anti-tumor necrosis factor therapy, and baseline patient-reported outcomes